Overview
A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma
Status:
Withdrawn
Withdrawn
Trial end date:
2013-05-01
2013-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to determine the safety and tolerability of 8.0 mg of ASM8 when given daily for 14 days by the Aeroneb® Go nebulizer to subjects with moderate to severe asthma.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pharmaxis
Criteria
Inclusion Criteria:- Be diagnosed with asthma for 3 or more months Have moderate to severe asthma as
defined by ATS criteria
Exclusion Criteria:
- No history of pulmonary or health problems for which the Investigator considers that
participation in this protocol is a risk for the subject